Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in WA17822

This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA). Patients enrolled in the WA18695 study had previously received treatment in the 24-week, placebo-controlled, Phase III Study WA17822. Eligible patients were assigned to treatment with 8 mg/kg tocilizumab every 4 weeks for a maximum of 5 years.

本项开放标签国际多中心扩展研究WA18695旨在评估托珠单抗（tocilizumab）在中度至重度活动性类风湿关节炎（rheumatoid arthritis, RA）患者中的长期安全性。参与本研究WA18695的受试者此前均已完成24周安慰剂对照III期临床试验WA17822的治疗。符合入组标准的患者将被分配至每4周给药一次8mg/kg托珠单抗的治疗方案，最长治疗时长不超过5年。